Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer
Recommended Citation
Patel SP, Gadgeel S, Mino-Kenudson M, Naidoo J, Sethakorn N. Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer. Cancer Treat Rev. 2026;143:103050.
Document Type
Article
Publication Date
2-1-2026
Publication Title
Cancer treatment reviews
Keywords
Humans, Carcinoma, Non-Small-Cell Lung, Immunoconjugates, Lung Neoplasms, Cell Adhesion Molecules, Antigens, Neoplasm, Antibodies, Monoclonal, Humanized, Camptothecin
Abstract
Lung cancer remains the leading cause of cancer-related death in the United States, with non-small cell lung cancer (NSCLC) accounting for most lung cancer cases. Improvements in first-line treatment with immuno-oncology and targeted therapies have been observed in patients with NSCLC, but benefits may be limited for those with advanced or metastatic NSCLC (mNSCLC). Following progression on frontline therapies, later-line therapies offer modest benefits and are associated with pronounced adverse effects. Accordingly, there is a need for new, more effective options to improve survival and quality of life. Trophoblast surface antigen 2 (TROP2) antibody-drug conjugates (ADCs) are a novel approach to address unmet treatment needs in NSCLC. There are 5 TROP2-directed ADCs currently under investigation for treatment of NSCLC: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan, DB-1305, and SHR-A1921. Here, we provide an overview of the properties of each ADC as well as efficacy and safety data from clinical trials of patients with NSCLC with or without actionable genomic alterations (AGAs). The unique characteristics of each ADC and its components, particularly the linker chemistry and payload attributes, define the mechanism of action and subsequently influence dosing, efficacy, and safety. TROP2 ADCs have shown antitumor responses with a manageable safety profile in patients with mNSCLC in several ongoing and completed trials. Additional studies are required to understand how these agents can be effectively integrated into the treatment paradigm for lung cancer, taking into consideration sequential use of multiple ADCs, resistance mechanisms, combination therapies, and use in special populations.
Medical Subject Headings
Humans; Carcinoma, Non-Small-Cell Lung; Immunoconjugates; Lung Neoplasms; Cell Adhesion Molecules; Antigens, Neoplasm; Antibodies, Monoclonal, Humanized; Camptothecin
PubMed ID
41512604
Volume
143
First Page
103050
Last Page
103050
